DE60139339D1 - Stabilisierte interferonzusammensetzungen - Google Patents

Stabilisierte interferonzusammensetzungen

Info

Publication number
DE60139339D1
DE60139339D1 DE60139339T DE60139339T DE60139339D1 DE 60139339 D1 DE60139339 D1 DE 60139339D1 DE 60139339 T DE60139339 T DE 60139339T DE 60139339 T DE60139339 T DE 60139339T DE 60139339 D1 DE60139339 D1 DE 60139339D1
Authority
DE
Germany
Prior art keywords
interferon compositions
stabilized interferon
stabilized
compositions
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60139339T
Other languages
English (en)
Inventor
Emerville Wolfe
Emeryville Hora
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Application granted granted Critical
Publication of DE60139339D1 publication Critical patent/DE60139339D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60139339T 2000-11-07 2001-11-07 Stabilisierte interferonzusammensetzungen Expired - Lifetime DE60139339D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24645600P 2000-11-07 2000-11-07
US25222400P 2000-11-21 2000-11-21
PCT/US2001/047514 WO2002038170A2 (en) 2000-11-07 2001-11-07 Stabilized inteferon compositions

Publications (1)

Publication Number Publication Date
DE60139339D1 true DE60139339D1 (de) 2009-09-03

Family

ID=26937990

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60139339T Expired - Lifetime DE60139339D1 (de) 2000-11-07 2001-11-07 Stabilisierte interferonzusammensetzungen

Country Status (16)

Country Link
US (2) US6994847B2 (de)
EP (1) EP1343518B1 (de)
JP (2) JP4129178B2 (de)
CN (1) CN1330372C (de)
AU (2) AU2002230707B2 (de)
BG (1) BG66082B1 (de)
CA (1) CA2428144C (de)
CZ (1) CZ20031259A3 (de)
DE (1) DE60139339D1 (de)
ES (1) ES2330508T3 (de)
HU (1) HU228583B1 (de)
IL (2) IL155788A0 (de)
NO (1) NO330690B1 (de)
PL (1) PL209928B1 (de)
PT (1) PT1343518E (de)
WO (1) WO2002038170A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
WO2005011605A2 (en) * 2003-08-01 2005-02-10 Medarex, Inc. Combination therapies for multiple sclerosis
US7276275B2 (en) * 2004-04-22 2007-10-02 Highland Industries, Inc. Laminated spacer fabric
JP5385529B2 (ja) * 2004-04-22 2014-01-08 ハイランド インダストリーズ，インコーポレーテッド スペーサファブリック
EP1888637A2 (de) 2005-05-19 2008-02-20 Amgen Inc. Zusammensetzungen und verfahren zur erhöhung der stabilität von antikörpern
CN101198328B (zh) * 2005-06-21 2011-04-06 默克专利股份有限公司 含有（r）-（-）-2-[5-（4-氟苯基）-3-吡啶基甲基氨基甲基]苯并二氢吡喃的固体药物制剂
MX2009003982A (es) 2006-10-20 2009-04-27 Amgen Inc Formulaciones de polipeptido estables.
CN101190329B (zh) * 2006-11-29 2013-03-06 信谊药厂 一种重组人p43蛋白的药物组合物及其在医药上的应用
NZ580686A (en) 2007-05-02 2012-11-30 Ambrx Inc Modified interferon beta polypeptides and their uses
JP2011195557A (ja) * 2010-02-24 2011-10-06 Kyorin Pharmaceutical Co Ltd 糖アルコールの選択方法
MX2012010148A (es) * 2010-03-04 2013-01-22 Pfenex Inc Metodo para producir proteinas de interferon recombinantes solubles sin desnaturalizacion.
CN102585011A (zh) * 2012-02-10 2012-07-18 中国农业大学 一种犬α干扰素衍生物的制备方法与应用
EA038462B1 (ru) 2014-10-23 2021-08-31 Эмджен Инк. Снижение вязкости фармацевтических составов
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
US10799639B2 (en) * 2017-03-03 2020-10-13 Min Wei Syringe type medication delivery device
CN113797318B (zh) * 2021-10-26 2023-06-30 深圳科兴药业有限公司 一种干扰素组合物及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4439181A (en) 1981-01-26 1984-03-27 Regents Of The University Of Minnesota Polyol-hormone mixture for use in chronic parenteral hormone administration
JPS5821691A (ja) * 1981-07-29 1983-02-08 Mochida Pharmaceut Co Ltd α−及びβ−インタ−フェロンの精製方法
EP0080879B1 (de) 1981-11-28 1986-10-01 Sunstar Kabushiki Kaisha Stabilisiertes Interferon enthaltende pharmazeutische Zusammensetzung
AU1234383A (en) 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
US4462940A (en) 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US5643566A (en) 1982-09-23 1997-07-01 Cetus Corporation Formulation processes for lipophilic proteins
US4992271A (en) 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US5702699A (en) 1982-09-23 1997-12-30 Cetus Corporation Process for the recovery of lipophilic proteins
DE3484374D1 (de) 1983-08-04 1991-05-08 Green Cross Corp Gamma-interferonzusammensetzung.
JPS6069037A (ja) 1983-09-26 1985-04-19 Sunstar Inc エリテマト−デス治療用外用剤
JPS61500439A (ja) 1983-11-21 1986-03-13 リ−ジエンツ　オヴ　ザ　ユニヴア−シテイ−　オヴ　ミネソタ 慢性的非経口ホルモン投与用緩衝化ポリオ−ル−ホルモン混合物
US4605555A (en) 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
US4816440A (en) 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US4808705A (en) * 1986-12-19 1989-02-28 Cetus Corporation Stable formulations of ricin toxin a chain and of RTA-immunoconjugates and stabilizer screening methods therefor
US4894330A (en) * 1986-12-23 1990-01-16 Cetus Corporation Purification of recombinant beta-interferon incorporating RP-HPLC
EP0284249A1 (de) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Gefriergetrocknete Lymphokin-Zusammensetzung
IT1222427B (it) * 1987-07-31 1990-09-05 Sclavo Spa Procedimento per la purificazione di interferone
US5151265A (en) 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
US5004605A (en) 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
IL89662A (en) * 1989-03-19 1997-11-20 Interpharm Lab Ltd Kiryat Weiz Pharmaceutical compositions comprising interferon-beta
EP0410207B1 (de) 1989-07-24 1997-01-22 Bayer Corporation Stabilisierung von hochgereinigten Proteinen
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
TW249202B (de) 1993-08-13 1995-06-11 Ciba Gerigy Corp
FR2710637B1 (fr) 1993-09-28 1995-12-08 Roquette Freres Mannitol pulvérulent de friabilité modérée et son procédé de préparation.
FR2719479B1 (fr) 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US5542303A (en) * 1994-05-12 1996-08-06 Neuffer; A. Erich Dual-peak torque measuring apparatus
IT1272252B (it) 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
NZ285664A (en) * 1994-05-18 1998-07-28 Inhale Therapeutic Syst Dry powder interferon composition adapted for pulmonary delivery
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
EP0875253B1 (de) 1997-05-02 2005-04-06 Seikagaku Corporation Chondroitinase enthaltende Zusammensetzungen
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta

Also Published As

Publication number Publication date
US20060008447A1 (en) 2006-01-12
ES2330508T3 (es) 2009-12-11
US7662369B2 (en) 2010-02-16
PT1343518E (pt) 2009-08-03
CA2428144C (en) 2012-01-10
WO2002038170A2 (en) 2002-05-16
HU228583B1 (en) 2013-04-29
EP1343518B1 (de) 2009-07-22
PL366329A1 (en) 2005-01-24
NO20032033D0 (no) 2003-05-06
PL209928B1 (pl) 2011-11-30
BG107887A (bg) 2004-01-30
CA2428144A1 (en) 2002-05-16
BG66082B1 (bg) 2011-03-31
AU2002230707B2 (en) 2006-08-24
IL155788A0 (en) 2003-12-23
EP1343518A2 (de) 2003-09-17
AU3070702A (en) 2002-05-21
JP4129178B2 (ja) 2008-08-06
CN1481252A (zh) 2004-03-10
JP2008069171A (ja) 2008-03-27
NO330690B1 (no) 2011-06-14
US20020114782A1 (en) 2002-08-22
HUP0301653A3 (en) 2009-03-30
CZ20031259A3 (cs) 2004-01-14
JP2004536021A (ja) 2004-12-02
US6994847B2 (en) 2006-02-07
NO20032033L (no) 2003-07-03
HUP0301653A2 (en) 2007-02-28
CN1330372C (zh) 2007-08-08
IL155788A (en) 2013-09-30
WO2002038170A3 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
ATE303787T1 (de) Schergelzusammensetzungen
DE60142412D1 (de) Stabilisiertes interleukin 2
IS2932B (is) Fúlvestrant samsetning
FI20010780A0 (fi) Parannetut koostumukset
AR028197A1 (es) Composiciones antitranspirantes
DE60118496D1 (de) Pulverzusammensetzung
FI20105657A (fi) Farmaseuttisia koostumuksia
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
ITMI20010748A0 (it) Composizioni farmaceutiche
AR023440A1 (es) Composiciones antitranspirantes
BR0210619A (pt) composição
ATE257691T1 (de) Schweisshemmende zusammensetzungen
IS7081A (is) Lyfjablanda
ATE369830T1 (de) Schweisshemmende zusammensetzungen
DE60139339D1 (de) Stabilisierte interferonzusammensetzungen
ATE314049T1 (de) Schweisshemmende zusammensetzungen
NO20026123L (no) Farmasöytiske sammensetninger
DE60116858D1 (de) Zusammensetzung
NO20031095L (no) Farmasoytiske sammensetninger
ATE266316T1 (de) Fungizide zusammensetzungen
DE60104098D1 (de) Brennstoffzusammensetzung
NO20020524L (no) Stabiliserte organisk-peroksid sammensetninger
ITTO20020744A0 (it) Composizione
DE60107312D1 (de) Feste Zusammensetzung
DE60135223D1 (de) Shampoozusammensetzungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition